Article Sidebar

PDF
Date Published: 15/04/2023
Online Published: 15/04/2023
Abstract Views: 357
Views PDF: 190
DOI: https://doi.org/10.58490/ctump.2023i58.699
Issue
No. 58 (2023): HỘI NGHỊ KHOA HỌC QUỐC TẾ MỞ RỘNG LẦN THỨ II NĂM 2023
Section
Article
How to Cite
Tran, T. T. N., Le, H. L., Nguyen, T. Q., Nguyen, T. T. T., & Tran, Q. H. (2023). THE IMPORTANT ROLE OF INTERLEUKIN 6 IN COVID-19. Cantho Journal of Medicine and Pharmacy, 58, 103-113. https://doi.org/10.58490/ctump.2023i58.699

THE IMPORTANT ROLE OF INTERLEUKIN 6 IN COVID-19

Thi Thuy Nga Tran1, Huong Ly Le1, Thanh Quang Nguyen1, Thi Thu Trang Nguyen1, Que Huong Tran1,
1 Da Nang University of Medical Technology and Pharmacy

Main Article Content

Abstract

A novel coronavirus, severe acute respiratory syndrome‐coronavirus 2 (SARS‐CoV‐2), emerged in December 2019 from Wuhan, China. SAR-CoV-2 virus can trigger the body's immune responses. Several studies have demonstrated that elevated levels of interleukin 6 (IL-6) are strongly associated with severe COVID-19 patients. IL-6 is a cytokine with many biological functions in the body's immunity, regeneration, and metabolism. Overproduction of cytokines including IL-6 leads to cytokine release syndrome (CRS), also known as cytokine storm, an uncontrolled systemic inflammation that leads to multi-organ failure and even death in COVID-19 patients. Therefore, blocking the IL-6 signaling pathway is expected to become a potential method to limit the serious complications of CRS syndrome. In this review, the important role of IL-6 and effective therapies for the treatment of cytokine storms are analyzed and discussed.

Article Details

Keywords

COVID-19, Interleukin 6, CRS

References

1. Who.int. (2021, 30/9/2021). WHO Coronavirus (COVID-19) Dashboard. Available: https://covid19.who.int/
2. C. Zanza et al., "Cytokine Storm in COVID-19: Immunopathogenesis and Therapy," Medicina (Kaunas), vol. 58, no. 2, Jan 18 2022.
3. Nih.gov. (31/12/2022). Covid-19 Treatment Guidelines. Available: https://www.covid19treatmentguidelines.nih.gov/
4. P. Sabaka et al., "Role of interleukin 6 as a predictive factor for a severe course of Covid-19: retrospective data analysis of patients from a long-term care facility during Covid-19 outbreak," BMC Infect Dis, vol. 21, no. 1, p. 308, Mar 29 2021.
5. S. A. Jones and C. A. Hunter, "Is IL-6 a key cytokine target for therapy in COVID-19?," Nat Rev Immunol, vol. 21, no. 6, pp. 337-339, Jun 2021.
6. C. Zhang, Z. Wu, J. W. Li, H. Zhao, and G. Q. Wang, "Cytokine release syndrome in severe COVID-19: interleukin-6 receptor antagonist tocilizumab may be the key to reduce mortality," Int J Antimicrob Agents, vol. 55, no. 5, p. 105954, May 2020.
7. T. Tanaka, A. Ogata, and M. Narazaki, "Tocilizumab: An Updated Review of Its Use in the Treatment of Rheumatoid Arthritis and Its Application for Other Immune-Mediated Diseases," Clinical Medicine Insights: Therapeutics, vol. 5, p. CMT.S9282, 2013/01/01 2013.
8. W. Somers, M. Stahl, and J. S. Seehra, "1.9 A crystal structure of interleukin 6: implications for a novel mode of receptor dimerization and signaling," Embo j, vol. 16, no. 5, pp. 989-97, Mar 3 1997.
9. I. L. Indalao et al, "IL-1β is a key cytokine that induces trypsin upregulation in the influenza virus-cytokine-trypsin cycle," Arch Virol, vol. 162, no. 1, pp. 201-211, Jan 2017.
10. T. Patra et al., "SARS-CoV-2 spike protein promotes IL-6 trans-signaling by activation of angiotensin II receptor signaling in epithelial cells," PLoS Pathog, vol. 16, no. 12, p. e1009128, Dec 2020.
11. S. Kaur, Y. Bansal and G. Bansal, "A panoramic review of IL-6: Structure, pathophysiological roles and inhibitors," Bioorg Med Chem, vol. 28, no. 5, p. 115327, Mar 1 2020.
12. Y. Xu et al., "Crystal structure of the entire ectodomain of gp130: insights into the molecular assembly of the tall cytokine receptor complexes," J Biol Chem, vol. 285, no. 28, pp. 21214-8, Jul 9 2010.
13. S. Rose-John, "IL-6 trans-signaling via the soluble IL-6 receptor: importance for the proinflammatory activities of IL-6," Int J Biol Sci, vol. 8, no. 9, pp. 1237-47, 2012.
14. Z. Yang et al, "The effect of corticosteroid treatment on patients with coronavirus infection: a systematic review and meta-analysis," J Infect, vol. 81, no. 1, pp. e13-e20, Jul 2020.
15. F. Angriman et al., "Interleukin-6 receptor blockade in patients with COVID-19: placing clinical trials into context," Lancet Respir Med, vol. 9, no. 6, pp. 655-664, Jun 2021.
16. A. Esmaeilzadeh and R. Elahi, "Immunobiology and immunotherapy of COVID-19: A clinically updated overview," Journal of cellular physiology, vol. 236, no. 4, pp. 2519-2543, 2021/04// 2021.
17. X. Wang, Z. He, and X. Zhao, "Immunoregulatory therapy strategies that target cytokine storms in patients with COVID-19 (Review)," Exp Ther Med, vol. 21, no. 4, p. 319, Apr 2021.
18. E. J. Kooistra et al., "Anakinra treatment in critically ill COVID-19 patients: a prospective cohort study," Crit Care, vol. 24, no. 1, p. 688, Dec 10 2020.
19. P. Richardson et al., "Baricitinib as potential treatment for 2019-nCoV acute respiratory disease," Lancet, vol. 395, no. 10223, pp. e30-e31, Feb 15 2020.
20. J. Alijotas-Reig et al., "Immunomodulatory therapy for the management of severe COVID-19. Beyond the anti-viral therapy: A comprehensive review," Autoimmun Rev, vol. 19, no. 7, p. 102569, Jul 2020.
21. J. S. Kim et al., "Immunopathogenesis and treatment of cytokine storm in COVID-19," Theranostics, vol. 11, no. 1, pp. 316-329, 2021.
22. M. Abbattista, I. Martinelli, and F. Peyvandi, "Comparison of adverse drug reactions among four COVID-19 vaccines in Europe using the EudraVigilance database: Thrombosis at unusual sites," J Thromb Haemost, vol. 19, no. 10, pp. 2554-2558, Oct 2021.
23. Y. Z. Huang and C. C. Kuan, "Vaccination to reduce severe COVID-19 and mortality in COVID19 patients: a systematic review and meta-analysis," Eur Rev Med Pharmacol Sci, vol. 26, no. 5, pp. 1770-1776, Mar 2022.